NEW YORK, April 17, 2019 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD), Liquidia Technologies, Inc. (NASDAQ:LQDA), Taylor Devices, Inc. (NASDAQ:TAYD), Kingstone Companies, Inc (NASDAQ:KINS), Aerpio Pharmaceuticals, Inc. (NASDAQ:ARPO), and Pingtan Marine Enterprise Ltd. (NASDAQ:PME), including updated fundamental summaries, consolidated fiscal reporting, and fully-qualified certified analyst research.

Complimentary Access: Research Reports

Full copies of recently published reports are available to readers at the links below.

GLMD DOWNLOAD: http://Fundamental-Markets.com/register/?so=GLMD
LQDA DOWNLOAD: http://Fundamental-Markets.com/register/?so=LQDA
TAYD DOWNLOAD: http://Fundamental-Markets.com/register/?so=TAYD
KINS DOWNLOAD: http://Fundamental-Markets.com/register/?so=KINS
ARPO DOWNLOAD: http://Fundamental-Markets.com/register/?so=ARPO
PME DOWNLOAD: http://Fundamental-Markets.com/register/?so=PME

(You may have to copy and paste the link into your browser and hit the [ENTER] key)

The new research reports from Fundamental Markets, available for free download at the links above, examine Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD), Liquidia Technologies, Inc. (NASDAQ:LQDA), Taylor Devices, Inc. (NASDAQ:TAYD), Kingstone Companies, Inc (NASDAQ:KINS), Aerpio Pharmaceuticals, Inc. (NASDAQ:ARPO), and Pingtan Marine Enterprise Ltd. (NASDAQ:PME) on a fundamental level and outlines the overall demand for their products and services in addition to an in-depth review of the business strategy, management discussion, and overall direction going forward. Several excerpts from the recently released reports are available to today's readers below.

-----------------------------------------

Important Notice: the following excerpts are not designed to be standalone summaries and as such, important information may be missing from these samples. Please download the entire research report, free of charge, to ensure you are reading all relevant material information. Percentage calculations are performed after rounding. All amounts in millions (MM), except per share amounts.

-----------------------------------------

GALMED PHARMACEUTICALS LTD. (GLMD) REPORT OVERVIEW

Galmed Pharmaceuticals' Recent Financial Performance

For the three months ended December 31st, 2018 vs December 31st, 2017, Galmed Pharmaceuticals reported revenue of $0.00MM vs $0.27MM and analysts estimated basic earnings per share -$0.15 vs -$0.27. For the twelve months ended December 31st, 2018 vs December 31st, 2017, Galmed Pharmaceuticals reported revenue of $2.04MM vs $1.09MM (up 87.83%) and analysts estimated basic earnings per share -$0.54 vs -$0.98. Analysts expect earnings to be released on May 8th, 2019. The report will be for the fiscal period ending March 31st, 2019. The reported EPS for the same quarter last year was -$0.17. The estimated EPS forecast for the next fiscal year is -$1.47 and is expected to report on March 11th, 2020.

To read the full Galmed Pharmaceuticals Ltd. (GLMD) report, download it here: http://Fundamental-Markets.com/register/?so=GLMD

-----------------------------------------

LIQUIDIA TECHNOLOGIES, INC. (LQDA) REPORT OVERVIEW

Liquidia Technologies' Recent Financial Performance

For the twelve months ended December 31st, 2018 vs December 31st, 2017, Liquidia Technologies reported revenue of $2.71MM vs $7.26MM (down 62.70%) and analysts estimated basic earnings per share -$7.42 vs -$51.78. Analysts expect earnings to be released on May 28th, 2019. The report will be for the fiscal period ending March 31st, 2019. The estimated EPS forecast for the next fiscal year is -$2.33 and is expected to report on February 25th, 2020.

To read the full Liquidia Technologies, Inc. (LQDA) report, download it here: http://Fundamental-Markets.com/register/?so=LQDA

-----------------------------------------

TAYLOR DEVICES, INC. (TAYD) REPORT OVERVIEW

Taylor Devices' Recent Financial Performance

For the three months ended February 28th, 2019 vs February 28th, 2018, Taylor Devices reported revenue of $7.81MM vs $6.57MM (up 18.84%) and analysts estimated basic earnings per share $0.13 vs -$0.01. For the twelve months ended May 31st, 2018 vs May 31st, 2017, Taylor Devices reported revenue of $24.36MM vs $25.54MM (down 4.59%) and analysts estimated basic earnings per share $0.13 vs $0.68 (down 80.88%). Analysts expect earnings to be released on September 4th, 2019. The report will be for the fiscal period ending May 31st, 2019.

To read the full Taylor Devices, Inc. (TAYD) report, download it here: http://Fundamental-Markets.com/register/?so=TAYD

-----------------------------------------

KINGSTONE COMPANIES, INC (KINS) REPORT OVERVIEW

Kingstone Companies' Recent Financial Performance

For the three months ended December 31st, 2018 vs December 31st, 2017, Kingstone Companies reported revenue of $29.64MM vs $25.78MM (up 14.95%) and basic earnings per share -$0.09 vs $0.19. For the twelve months ended December 31st, 2018 vs December 31st, 2017, Kingstone Companies reported revenue of $113.77MM vs $92.77MM (up 22.64%) and analysts estimated basic earnings per share $0.29 vs $0.96 (down 69.79%). Analysts expect earnings to be released on May 8th, 2019. The report will be for the fiscal period ending March 31st, 2019. The reported EPS for the same quarter last year was -$0.22. The estimated EPS forecast for the next fiscal year is $1.40 and is expected to report on March 11th, 2020.

To read the full Kingstone Companies, Inc (KINS) report, download it here: http://Fundamental-Markets.com/register/?so=KINS

-----------------------------------------

AERPIO PHARMACEUTICALS, INC. (ARPO) REPORT OVERVIEW

Aerpio Pharmaceuticals' Recent Financial Performance

Analysts expect earnings to be released on May 21st, 2019. The report will be for the fiscal period ending March 31st, 2019. The reported EPS for the same quarter last year was -$0.27. The estimated EPS forecast for the next fiscal year is -$0.40 and is expected to report on March 3rd, 2020.

To read the full Aerpio Pharmaceuticals, Inc. (ARPO) report, download it here: http://Fundamental-Markets.com/register/?so=ARPO

-----------------------------------------

PINGTAN MARINE ENTERPRISE LTD. (PME) REPORT OVERVIEW

Pingtan Marine Enterprise's Recent Financial Performance

For the three months ended December 31st, 2018 vs December 31st, 2017, Pingtan Marine Enterprise reported revenue of $25.08MM vs $16.39MM (up 53.02%) and analysts estimated basic earnings per share -$0.04 vs $0.06. For the twelve months ended December 31st, 2018 vs December 31st, 2017, Pingtan Marine Enterprise reported revenue of $64.26MM vs $63.21MM (up 1.66%) and analysts estimated basic earnings per share $0.17 vs $0.38 (down 55.26%). Analysts expect earnings to be released on May 8th, 2019. The report will be for the fiscal period ending March 31st, 2019.

To read the full Pingtan Marine Enterprise Ltd. (PME) report, download it here: http://Fundamental-Markets.com/register/?so=PME

-----------------------------------------

ABOUT FUNDAMENTAL MARKETS

Fundamental Markets serves thousands of members and have provided research through some of the world's leading brokerages for over a decade–and continue to be one of the best information sources for investors and investment professionals worldwide. Fundamental Markets' roster boasts decades of financial experience and includes top financial writers, FINRA® BrokerCheck® certified professionals with current and valid CRD® number designations, as well as Chartered Financial Analyst® (CFA®) designation holders, to ensure up to date factual information for active readers on the topics they care about.

REGISTERED MEMBER STATUS

Fundamental Markets' oversight and audit staff are registered analysts, brokers, and/or financial advisers ("Registered Members") working within Equity Research, Media, and Compliance departments. Fundamental Markets' roster includes qualified CFA® charterholders, licensed securities attorneys, and registered FINRA® members holding duly issued CRD® numbers. Current licensed status of several Registered Members at Fundamental Markets have been independently verified by an outside audit firm, including policy and audit records duly executed by Registered Members. Complaints, concerns, questions, or inquiries regarding this release should be directed to Fundamental Markets' Compliance department by Phone, at +1 667-401-0010, or by E-mail at compliance@Fundamental-Markets.com.

LEGAL NOTICES

Information contained herein is not an offer or solicitation to buy, hold, or sell any security. Fundamental Markets, Fundamental Markets members, and/or Fundamental Markets affiliates are not responsible for any gains or losses that result from the opinions expressed. Fundamental Markets makes no representations as to the completeness, accuracy, or timeliness of the material provided and all materials are subject to change without notice. Fundamental Markets has not been compensated for the publication of this press release by any of the above mentioned companies. Fundamental Markets is not a financial advisory firm, investment adviser, or broker-dealer, and does not undertake any activities that would require such registration. For our full disclaimer, disclosure, and terms of service please visit our website.

Media Contact:
Arden Dalio, Media Department
Office: +1 667-401-0010
E-mail: media@Fundamental-Markets.com 

© 2019 Fundamental Markets. All Rights Reserved. For republishing permissions, please contact a partner network manager at partnership@Fundamental-Markets.com. 

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

FINRA®, BrokerCheck®, and CRD® are registered trademarks owned by Financial Industry Regulatory Authority, Inc.